Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.35 |
| ▸ | TET3 | O43151 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | FBXL19 | Q6PCT2 | 4/20 | 0.34 |
| ▸ | CXXC5 | Q7LFL8 | 4/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.34 |
| ▸ | CXXC4 | Q9H2H0 | 4/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 3/20 | 0.34 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21741286 | 0.79 | JAK3 (0.36) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL22967502 | 0.75 | JAK3 (0.34) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL20314920 | 0.75 | JAK3 (0.38) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL24244455 | 0.75 | KMT2A (0.44) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL25228712 | 0.72 | JAK3 (0.43) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL24829662 | 0.71 | TET3 (0.36) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL23158190 | 0.70 | TET3 (0.37) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL20547259 | 0.70 | TET3 (0.47) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL237862 | 0.70 | — | — | |
| SCHEMBL167151 | 0.70 | TET3 (0.47) | JAK3TET3KMT2AFBXL19CXXC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021023247-A1 | KRAS MUTANT PROTEIN INHIBITOR | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | WO | disclosed |